VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | ELOQUENT-2 trial of elotuzumab plus lenalidomide/dexamethasone in multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomized, open-label, phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter